2025
Acute Pain Management in People With Opioid Use Disorder : A Systematic Review.
Buonora M, Mackey K, Khalid L, Hickey T, Grimshaw A, Moss M, Starrels J, Alford D, Becker W, Weimer M. Acute Pain Management in People With Opioid Use Disorder : A Systematic Review. Annals Of Internal Medicine 2025, 178: 558-570. PMID: 40096692, DOI: 10.7326/annals-24-01917.Peer-Reviewed Original ResearchConceptsOpioid use disorderOUD outcomesAcute pain interventionsAcute pain managementPain interventionsPain outcomesEmergency departmentPain managementObservational studyUse disorderImprove pain-related outcomesPerioperative settingEffectiveness of pain interventionsPain-related outcomesWell-conducted randomized controlled trialsImprove pain outcomesAcute painful episodesStrength of evidence assessmentIntravenous (IVControlled observational studiesNon-U.S. populationsEffectiveness of interventionsRandomized Controlled TrialsOral clonidineRisk of bias
2024
Prospective and External Validation of an Ensemble Learning Approach to Sensitively Detect Intravenous Fluid Contamination in Basic Metabolic Panels
Spies N, Militello L, Farnsworth C, El-Khoury J, Durant T, Zaydman M. Prospective and External Validation of an Ensemble Learning Approach to Sensitively Detect Intravenous Fluid Contamination in Basic Metabolic Panels. Clinical Chemistry 2024, 71: 296-306. PMID: 39545815, DOI: 10.1093/clinchem/hvae168.Peer-Reviewed Original ResearchSHapley Additive exPlanationsLearning approachDetection of contamination eventsUnsupervised learning approachLearning-based methodsMachine learning-based methodsEnsemble learning approachMachine learning pipelineEnsemble learningLearning pipelineMatthews correlation coefficientAlgorithmic fairnessReal worldSHapley Additive exPlanations valuesCurrent workflowsClinical workflowWorkflowOperational burdenBasic metabolic panelIntravenous (IVPipelineInternal validation setValidation setFlagging ratesPerformance assessmentA first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
Papadopoulos K, Rodon Ahnert J, Khushman M, Sharma S, Pelster M, Cecchini M, Kummar S, Choi M, Akella L, Garofalo A, Yu Z, Iyer V, Nguyen M, Orford K, Klempner S. A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2024, 42: tps3175-tps3175. DOI: 10.1200/jco.2024.42.16_suppl.tps3175.Peer-Reviewed Original ResearchNon-small cell lung cancerMSS colorectal cancerMetastatic solid tumorsSolid tumorsColorectal cancerAdenomatous polyposis coliT cell factorB-cateninAntitumor activityWnt/b-cateninPhase 1/2 trialCell lung cancerFirst-in-humanTumor growth inhibitionActivate oncogenic pathwaysIntravenous (IVWnt pathwayPathway activating mutationsWnt/b-catenin pathwayWnt pathway genesCurative chemoradiationDose escalationDose expansionGastric/GEJ cancerEscalating dosesClinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review
Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan A. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review. Journal Of Oncology Pharmacy Practice 2024, 30: 721-736. PMID: 38509812, PMCID: PMC11118786, DOI: 10.1177/10781552241238979.Peer-Reviewed Original ResearchOral hypomethylating agentsAcute myeloid leukemiaHypomethylating agentsPK-PD profilesPharmacokinetic (PK)-pharmacodynamicMyeloid leukemiaTreatment selectionPK-PDConcentration-time curveIntravenous (IVImprove treatment outcomesCC-486IV decitabineOral azacitidineMaintenance therapySubcutaneous azacitidineNo significant differenceImprove quality of lifeAzacitidineClinical trialsClinical activityTreatment outcomesDisease settingsDecitabineDisease outcome
2023
Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions
Jumaa M, Rodriguez-Calienes A, Dawod G, Vivanco-Suarez J, Hassan A, Divani A, Oliver M, Ribo M, Petersen N, Abraham M, Fifi J, Guerrero W, Malik A, Siegler J, Nguyen T, Sheth S, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Galecio-Castillo M, Zevallos C, Malaga M, Farooqui M, Jovin T, Zaidi S, Ortega-Gutierrez S. Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions. Journal Of Stroke And Cerebrovascular Diseases 2023, 32: 107438. PMID: 37883826, PMCID: PMC11271813, DOI: 10.1016/j.jstrokecerebrovasdis.2023.107438.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageGP IIb/IIIa inhibitorsRate of symptomatic intracranial hemorrhageGP IIb/IIIaAntiplatelet therapyMechanical thrombectomyRetrospective non-randomized cohort studyGP IIb/IIIa inhibitor groupHemorrhagic infarction type 1Tandem lesionsComplete reperfusionType 1Periprocedural antiplatelet therapyReducing hemorrhage ratesParenchymal hematoma type 1Treatment of tandem lesionsNon-randomized cohort studyAcute carotid stentingIntravenous (IVGlycoprotein IIb/IIIa inhibitorsRate of complete reperfusionAssociated with increased oddsCangrelor groupHemorrhage rateIntravenous cangrelor
2021
Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone
Agin-Liebes G, Huhn A, Strain E, Bigelow G, Smith M, Edwards R, Gruber V, Tompkins D. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. Drug And Alcohol Dependence 2021, 226: 108869. PMID: 34216862, PMCID: PMC9559787, DOI: 10.1016/j.drugalcdep.2021.108869.Peer-Reviewed Original ResearchConceptsQuantitative sensory testingDoses of hydromorphoneAcute intravenous (IVLevel of opioid toleranceAbuse liability effectsAbuse liability measuresExperimental pain paradigmDoses of opioidsMethadone-maintained individualsAcute pain managementCumulative intravenous dosesIntravenous (IVOpioid use disorderRandomized Controlled StudyMethadone maintenance patientsPlacebo-controlled conditionsAnalgesic indexEfficacy opioidsQST outcomesEscalating dosesOpioid tolerancePlacebo doseOral methadoneAnalgesic strategiesAnalgesic responseExosomes of MSCs target M2-type Macrophages to promote TGF-β-Dependent Microvascular Stabilization and Functional Recovery in Spinal Cord Injury
Askenase P. Exosomes of MSCs target M2-type Macrophages to promote TGF-β-Dependent Microvascular Stabilization and Functional Recovery in Spinal Cord Injury. The Journal Of Immunology 2021, 206: 95.06-95.06. DOI: 10.4049/jimmunol.206.supp.95.06.Peer-Reviewed Original ResearchMesenchymal stromal cellsSpinal cord injuryM2-type macrophagesFractionated dosesTGF-bExpression of TGF-BMesenchymal stromal cell infusionInfusion of mesenchymal stromal cellsSevere contusion spinal cord injuryMSC-ExosTherapeutic effectInfused mesenchymal stromal cellsInjury siteBlood-spinal cord barrierTGF-B pathwayContusive spinal cord injuryCord injuryIntravenous (IVFunctional neurological recoverySprague Dawley ratsTight junction proteinsYoung Sprague Dawley ratsSingle doseDawley ratsNeurological recovery
2007
Stem Cell Transplantation: The Lung Barrier
Schrepfer S, Deuse T, Reichenspurner H, Fischbein M, Robbins R, Pelletier M. Stem Cell Transplantation: The Lung Barrier. Transplantation Proceedings 2007, 39: 573-576. PMID: 17362785, DOI: 10.1016/j.transproceed.2006.12.019.Peer-Reviewed Original ResearchConceptsMesenchymal stem cellsSodium nitroprussideMesenchymal stem cell passagingIV injectionMesenchymal stem cell injectionIntravenous (IVAssessed in vitroFluorescence-labeled microspheresMesenchymal stem cell migrationPulmonary microvasculatureTransplantation strategiesSN injectionInjured organsLung sectionsMouse mesenchymal stem cellsMSCs in vitroMesenchymal lineagesStem cellsLungLung capillariesCell trappingDifferentiation capacityPulmonary capillariesCellsInjection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply